Solid Biosciences heads into its June 10 earnings report with an unusual split: short interest climbing while the Street grows more bullish.
The earnings event is the lens through which everything else reads this week. The stock lost 8.5% on Tuesday alone — its sharpest single-day drop in recent weeks — and is now down 4.4% over the past five days and 7.7% over the past month, closing at $6.58. The next catalyst is just days away. SLDB's most recent track record around results is uneven: the stock fell 3.9% the day after its May 12 print, then shed another 21% over the following week. The March print produced a milder 1.3% next-day dip that later recovered. With results due June 10, the directional read from history is cautious.
Short positioning has tightened heading into that event, and the borrow market offers no particular squeeze signal. Short interest has risen 4.7% over the past week to 11.7% of the free float — a meaningfully elevated level for a micro-cap biotech. FINRA's official count of 9.1 million shares short, with days-to-cover of 6.8, confirms the short book is real and not trivially covered. But the lending market tells a very different story: availability is running at 534% of short interest, well above its 52-week low of 302%, meaning lenders are flush with supply relative to current demand. Borrow costs are low at 0.55% annualised, down 12% on the week. The combination — rising short interest, ample availability, cheap borrow — suggests bears are building positions methodically rather than being squeezed. The ORTEX short score of 63, which has held in a tight band between 62 and 65 all week, corroborates that reading: elevated but not extreme.
Options traders are leaning in the opposite direction. The put/call ratio at 0.52 is more than a standard deviation below its 20-day average of 0.59, meaning call volume is running ahead of what has been normal. That tilt toward calls, as the stock slides into an earnings week, reads as speculative positioning on a positive catalyst rather than protective hedging. The PCR has been drifting lower from the 0.67-0.69 range seen in late April and early May, a directional move that contrasts with the rising short interest.
The analyst community has moved in a firmly bullish direction this week. HC Wainwright raised its price target to $25 — from $20 — on June 3, maintaining its Buy. That is the single most meaningful recent action, and it arrived on the day the stock sold off 8.5%, which amplifies the divergence between analyst conviction and market behaviour. Looking at the broader Street, all recent coverage maintains positive ratings: Wedbush holds at Outperform with a $16 target, Piper Sandler sits at Overweight with an $18 target after raising it in May, and JP Morgan holds Overweight at $12. The mean analyst target is $17.38 — roughly 2.6 times the current price. The bull case centres on SGT-003, SLDB's DMD gene therapy candidate, the Phase 3 IMPACT study now enrolling, a cash runway extending to 2028, and FDA alignment on the regulatory path. The bear case is the one that has been playing out in the price: losses are widening, R&D costs are rising, and established competitors including Sarepta Therapeutics are already further down the commercialisation track. Factor scores offer limited comfort for bears: EPS momentum over 30 days ranks in the 88th percentile, and the EPS surprise score hits the 76th, suggesting recent estimate revisions have run ahead of the business.
Institutional ownership confirms that informed, long-only money is not walking away. The top three holders — Perceptive Advisors at 12.1%, Bain Capital Life Sciences at 10.0%, and RA Capital at 9.5% — together control nearly a third of shares outstanding. RA Capital added 3.5 million shares in the March quarter, and Vestal Point built a fresh 5.0 million-share stake. Janus Henderson and Deep Track Capital both initiated positions in the same period. These are not passive index funds; they are specialist life sciences managers who have looked at the SGT-003 data and added. Insider activity from February was a wave of small tax-withholding sales across the C-suite — procedural rather than signal-bearing.
Close peers have also had a rough week. EDIT dropped 15.6% on the day and 8.4% over the week; DYN fell 7.5% on Tuesday; DNTH shed 8.8%. The gene-therapy space is broadly under pressure, which frames SLDB's sell-off as sector rotation rather than company-specific news — though that distinction may matter less when earnings land on June 10. The key question going into that print is whether SGT-003 Phase 3 progress and updated cash runway guidance can interrupt the pattern of post-earnings weakness that has defined the stock's recent reaction history.
See the live data behind this article on ORTEX.
Open SLDB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
